ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,308.55
0.01%
Dow Jones
39,838.92
0.08%
US Dollar vs MXN
16.59168
0.22%
Brent Oil
82.33
-1.44%
Bitcoin
69,760.58
-2.38%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. SAB Biotherapeutics Inc (SABSW)

  7. SAB Biotherapeutics Inc (SABSW) Noticias

SABSW

SAB Biotherapeutics (SABSW)

SAB Biotherapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:SABSW
FechaHoraFuenteTítuloSímboloCompañía
21/05/202406:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SABSWSAB Biotherapeutics Inc
20/05/202416:45GlobeNewswire Inc.SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company UpdatesNASDAQ:SABSWSAB Biotherapeutics Inc
20/05/202415:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SABSWSAB Biotherapeutics Inc
06/05/202406:15GlobeNewswire Inc.SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of DirectorsNASDAQ:SABSWSAB Biotherapeutics Inc
16/04/202406:15GlobeNewswire Inc.SAB Biotherapeutics Provides SAB-142 Trial UpdateNASDAQ:SABSWSAB Biotherapeutics Inc
08/04/202406:15GlobeNewswire Inc.SAB Biotherapeutics to Present at INNODIA Annual MeetingNASDAQ:SABSWSAB Biotherapeutics Inc
04/04/202406:15GlobeNewswire Inc.SAB Biotherapeutics to Present at the Needham Virtual Healthcare ConferenceNASDAQ:SABSWSAB Biotherapeutics Inc
29/03/202406:15GlobeNewswire Inc.SAB Biotherapeutics Reports Full Year 2023 Operating and Financial ResultsNASDAQ:SABSWSAB Biotherapeutics Inc
25/03/202409:15GlobeNewswire Inc.SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza TreatmentNASDAQ:SABSWSAB Biotherapeutics Inc
23/02/202407:00GlobeNewswire Inc.SAB Biotherapeutics to Present at the BIO CEO & Investor ConferenceNASDAQ:SABSWSAB Biotherapeutics Inc
08/02/202407:00GlobeNewswire Inc.SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:SABSWSAB Biotherapeutics Inc
02/02/202406:30GlobeNewswire Inc.SAB Biotherapeutics Announces Executive Leadership ChangeNASDAQ:SABSWSAB Biotherapeutics Inc
23/01/202416:58GlobeNewswire Inc.SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:SABSWSAB Biotherapeutics Inc
02/01/202415:30GlobeNewswire Inc.SAB Biotherapeutics Announces 1-for-10 Reverse Stock SplitNASDAQ:SABSWSAB Biotherapeutics Inc
29/11/202306:30GlobeNewswire Inc.SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 DiabetesNASDAQ:SABSWSAB Biotherapeutics Inc
20/11/202306:30GlobeNewswire Inc.SAB Biotherapeutics Appoints Katie Ellias to the Board of DirectorsNASDAQ:SABSWSAB Biotherapeutics Inc
14/11/202306:30GlobeNewswire Inc.SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 DiabetesNASDAQ:SABSWSAB Biotherapeutics Inc
14/11/202306:15GlobeNewswire Inc.SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company UpdatesNASDAQ:SABSWSAB Biotherapeutics Inc
09/11/202306:30GlobeNewswire Inc.SAB Biotherapeutics to Present at Piper Sandler Healthcare ConferenceNASDAQ:SABSWSAB Biotherapeutics Inc
24/10/202306:30GlobeNewswire Inc.SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial OfficerNASDAQ:SABSWSAB Biotherapeutics Inc
19/10/202306:30GlobeNewswire Inc.SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 DiabetesNASDAQ:SABSWSAB Biotherapeutics Inc
05/10/202306:30GlobeNewswire Inc.SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of DirectorsNASDAQ:SABSWSAB Biotherapeutics Inc
02/10/202306:30GlobeNewswire Inc.SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 DiabetesNASDAQ:SABSWSAB Biotherapeutics Inc
21/08/202307:30GlobeNewswire Inc.SAB Biotherapeutics Provides Company Update for Q2 2023 Financial ResultsNASDAQ:SABSWSAB Biotherapeutics Inc
21/06/202307:30GlobeNewswire Inc.SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023NASDAQ:SABSWSAB Biotherapeutics Inc
30/05/202307:30GlobeNewswire Inc.SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International ConventionNASDAQ:SABSWSAB Biotherapeutics Inc
19/05/202307:30GlobeNewswire Inc.SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy InnovationsNASDAQ:SABSWSAB Biotherapeutics Inc
16/05/202307:30GlobeNewswire Inc.SAB Biotherapeutics Provides Company Update for Q1 2023 Financial ResultsNASDAQ:SABSWSAB Biotherapeutics Inc
12/05/202307:30GlobeNewswire Inc.SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal AntibodiesNASDAQ:SABSWSAB Biotherapeutics Inc
09/05/202307:30GlobeNewswire Inc.SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ PlatformNASDAQ:SABSWSAB Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SABSW

Su Consulta Reciente

NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
NVDA
NVIDIA
NYSE
CVX
Chevron
NYSE
MRK
Merck
NYSE
XOM
Exxon Mobil
COIN
BTCUSD
Bitcoin
USOTC
BNPQY
BNP Paribas (QX)
AMEX
SPY
SPDR S&P 500
CCOM
OILBRENT
Brent Oil
FX
USDMXN
US Dollar vs MXN
NYSE
NKE
Nike
NASDAQ
AMZN
Amazon.com
FX
EURMXN
Euro vs MXN
COIN
ETHUSD
Ethereum
NASDAQ
MSFT
Microsoft
COIN
SOLUSD
Solana
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados